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Abstract
Peptidomimetics designed to target voltage-gated sodium channels have attracted
significant attention as potential analgesics. However, voltage-gated sodium channel
(VGSC)-blocking activity of these compounds has mainly been assessed using rat
and/or mice homologs. In this study, we developed a novel series of conformationally
constrained peptidomimetic analogues of the μ-conotoxin KIIIA and assessed their
activity against human VGSCs. Two of the mimetics block the currents of hNav1.4
and hNav1.6 channels. NMR derived structures of the mimetics provided excellent
insight into the structural requirements for bioactivity. A lactam-constrained ana-
logue, previously reported to be active in mice, did not block the corresponding
human VGSC. This work highlights important differences in VGSCs between species
and validates the potential of peptidomimetics as human analgesics.
1 | INTRODUCTION
Conotoxin peptides are isolated from the venom of fish hunting
marine snails, which use them as an efficient means of prey incapaci-
tation and as an effective defense mechanism. Conotoxin venom has
been reported to have caused several human fatalities[1–3] and can
pose a risk to human health.[4] However, conotoxins and their syn-
thetic mimetics have attracted a substantial amount of interest due to
their properties as selective chemical probes that target ion channels
and receptors.[5–8] They are potential therapeutic leads for several
clinical applications including the treatment of neuropathic pain,
hypertension and type 2 diabetes.[9] Ziconotide, a synthetic analogue
of the conotoxin peptide ω-MVIIA is licensed for clinical use in the
treatment of severe and chronic pain.[10] Due to unfavorable physico-
chemical properties of the native peptides the development of con-
otoxin peptidomimetics has been an active field of study by
academics and the pharmaceutical industry.[11] Development of new
peptidomimetic chemistries that can be used to overcome the physi-
cochemical limitations of native peptides and provide peptide leads
for drug discovery are a high priority. This is generally achieved by
chemically modifying the peptide structure, removing the vulnerable
functionalities and introducing mimetic features to retain the overall
three-dimensional bioactive conformation of the peptide.
μ-Conotoxin KIIIA (μ-KIIIA) is isolated from the venom of the
marine cone snail Conus kinoshitai.[12] The peptide primary sequence
contains 16 amino acid residues that are constrained by three disul-
fide bonds to adopt an α-helical secondary structure. As with other
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μ-conotoxins, μ-KIIIA modulates the activity of voltage-gated sodium
channels (VGSCs) by occluding the pore in the middle of the channel.
VGSCs are heterotrimeric protein complexes composed of one
α-subunit and two β-subunits that form a single pore. The ion-conducting
core subunits (α-subunits) are solely required for voltage-dependent ion
permeation, and the β-subunits are responsible for regulating membrane
trafficking and channel properties.[13] Nine different subtypes of the
α-subunit of VGSCs have been identified in humans: Nav1.1-Nav1.9. Sub-
types Nav1.1, Nav1.2, Nav1.3, and Nav1.6 are primarily located in the
central nervous system (CNS). Nav1.4 functions in skeletal muscle and
Nav1.5 in the heart. Nav1.7, Nav1.8, and Nav1.9 are mainly found in the
peripheral nervous system.
The first structure of a human VGSC (Nav1.4-β1 complex) was
solved to 3.2 Å resolution using cryo-electron microscopy in 2018.[14]
This was followed in 2019 by the cryo-EM structure of μ-KIIIA bound
to human VGSC Nav1.2.
[15] The cryo-EM structure of human Nav1.7
in complex with auxiliary subunits and animal toxins has also recently
been reported.[16] These structures provide detailed information on
the molecular mechanisms of VGSC blocking by peptide ligands and
may potentially facilitate VGSC structure-based drug discovery.
Subtype Nav1.7 has been identified as a therapeutic target for
the treatment of pain through genetic association with gain-of-
function mutations in the SCN9A gene as the basis of inherited pain
syndromes, including erythromelalgia and paroxysmal extreme pain
disorder.[17] μ-KIIIA has rank order selectivity of Nav1.4 (48 ± 6
nM) ≥ Nav1.2 (61 ± 5 nM) > Nav1.6 (183 ± 31 nM) > Nav1.3
(3.6 ± 0.3 μM), and has no effect on Nav1.5 and Nav1.8 (at 10 μM).[18]
Numerous peptidomimetic strategies have been applied to
μ-conotoxins including peptide sequence miniaturization,[19] N- and
C-terminal extension,[20] chimeras,[21] and small molecule
mimietics.[22] Previous research by Norton and co-workers examined
the effect of μ-KIIIA peptidomimetics, incorporating a lactam confor-
mational constraint, on the VGSC subtypes Nav1.1-1.9.
[23] A
[D9K13]-lactam analogue was identified with an IC50 of 54 μM
against rat NaV1.4 and 40 μM against mouse NaV 1.6.[23]
This synthetic peptidomimetic strategy provides ready access to ana-
logues to determine structure-activity-relationships and information on
key functionalities required for the selective interaction with this impor-
tant class of therapeutic target.[23] However, one limitation of previous
studies is the use of rat and/or mouse sodium channels. Although rodent
and human voltage-gated sodium channels have a high degree of amino
acid sequence homology (ex. 92% sequence homology between human
and rat NaV1.4), their sensitivity to ligands often differs between spe-
cies.[24] The origin of these differences in many cases has yet to be eluci-
dated, yet is likely to be revealed as more ion-channel structures are
solved. The use of human VGSCs, expressed in human cells would give
the most relevant data to underpin and expedite a medicinal chemistry
programme.
The aim of the present work was to investigate whether syn-
thetic conformational constraints could replace the complex disulfide
bond bridging network in the μ-KIIIA conotoxin peptide, and produce
more stable analogues that would retain bioactivity against human
VGSCs.
2 | MATERIALS AND METHODS
2.1 | General information
Standard Fmoc-protected amino acids were purchased from CEM
Corporation or Pepceuticals and 2-(6-chloro-1H-benzotriazole-1-yl)-
1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), peptide
grade dimethyl formaldehyde (DMF) and ethyl (hydroxyimino)
cyanoacetate (Oxyma Pure) were purchased from Pepceuticals. (R)-N-
Fmoc-α-(7-octenyl)alanine was purchased from Nagase Europe
(GmbH) and (S)-N-Fmoc-α-(4-pentenyl)alanine was purchased from
Sigma Aldrich. Fmoc-Asp(O-2-PhiPr)-OH and Fmoc-Lys(Mmt)-OH
were purchased from Merck. 2,4,6-Triisopropylbenzenesulfonyl
hydrazide (TPSH) was purchased from TCI Chemicals. All other
reagents were purchased from Sigma Aldrich.
Flash column chromatography was performed on a Biotage Isolera
using prepacked KP-SIL silica gel SNAP cartridges (50 μm). Thin layer
chromatography was run on aluminium-backed plates precoated with
silica gel 60F254 (Merck) and spots were visualized with a UV lamp or
stained with ninhydrin. Spectra were recorded on a 400, 500, or
600 MHz Bruker NMR spectrometer, and chemical shifts are reported
in parts per million and corrected relative to the solvent as internal stan-
dard (CDCl3, δ 7.26). Multiplicity is reported as follows: s, singlet; d, dou-
blet; t, triplet; m, multiplet; br s, broad singlet. IR was run on a Nicolet
iS5 from Thermo Fisher mounted with an iD5 ATR. Optical rotation was
measured on an Autopol V automatic polarimeter (Rudolph Research
Analytical) using the sodium D line at 589 nm.
Peptides were synthesized on a Biotage Initiator + Alstra microwave
assisted peptide synthesizer. Reactions requiring microwave heating
were perfomed using a CEM Discover SP microwave. Peptides were
purified on a reverse-phase Dionex high performance liquid chromatog-
raphy (HPLC) system equipped with Dionex P680 pumps and a Dionex
UVD170U UV-vis detector (monitoring at 214 nm and 280 nm), using a
Phenomenex Gemini, C18, 5 μm, 250 x 21.2 mm column. Gradients
were run using a solvent system consisting of A (H2O + 0.1% TFA) and B
(H2O + 0.1% TFA), and collected fractions were lyophilised on a Christ
Alpha 2-4 LO plus freeze dryer.
Pure peptides were analyzed on a Shimadzu reverse-phase HPLC
(RP-HPLC) system equipped with Shimadzu LC-20AT pumps, a
Shimadzu SIL-20A autosampler and a Shimadzu SPD-20A UV-vis
detector (monitoring at 214 nm and 280 nm) using a Phenomenex,
Aeris, 5 μm, peptide XB-C18, 150 × 4.6 mm column at a flow rate of
1 mL/min. RP-HPLC gradients were run using a solvent system con-
sisting of solution A (5% acetonitrile [MeCN] in H2O + 0.1% TFA) and
B (5% H2O in MeCN +0.1% TFA). Two gradients were used to charac-
terize each peptide; a gradient from 0% to 100% solution B over
20 minutes and either a 50 minutes gradient from 0%-100% solution
B or a 25 minutes gradient from 0-50% solution B, respectively. Ana-
lytical RP-HPLC data is reported as column retention time (tR) in
minutes (min). Low resolution mass spectrometry (LRMS) was per-
formed on a Thermo Scientific LCQ Fleet quadrupole mass spectrom-
eter using positive mode electrospray ionization (ESI+). High
resolution mass spectrometry (HRMS) was performed on a Bruker
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microTOF-Q II (ESI+). HRMS data are reported as mass to charge ratio
(m/z) = observed / MW.
Peptide content was analyzed on a Nanodrop 2000c using UV
absorption of peptides at 280 nm.
2.2 | Peptide synthesis
Peptides were synthesized on 0.1 mmol scale using ChemMatrix Rink
Amide Resin (0.47 mmol/g) (Biotage). Couplings were performed using
4 equivalents Fmoc-protected amino acid, 4 equivalents HCTU and
4 equivalents diisopropylethylamine (DIPEA) in DMF (3 mL). Coupling of
standard Fmoc-protected amino acids was carried out for 10 minutes at
75 !C followed by 4 × 45 seconds washes. Arginine was double coupled;
60 minutes at room temperature followed by 5 minutes at 75 !C and
repeated with fresh reagents followed by washing. Histidine and cysteine
were coupled at room temperature for 5 minutes followed by 50 !C for
5 minutes and washes. For coupling of unnatural amino acids only
2 equivalents of reagents were used.
Deprotection was carried out in 20% piperidine in DMF + 0.1 M
Oxyma Pure (4.5 mL) for 30s and then 3 minutes at 75 !C followed by
washing. Following coupling of Fmoc-Asp(tBu)-OH all Fmoc-
deprotections were carried out at room temperature for 3 minutes
and then 10 minutes followed by washing. N-terminal acetylation was
performed using 1 mL 5 M acetic anhydride in DMF and 2.5 mL 2 M
DIPEA in NMP for 10 minutes at room temperature.
Test cleavages were performed in a cleavage cocktail (1 mL) of
95% trifluoroacetic acid (TFA), 2.5% water (H2O) and 2.5%
triisopropylsilane (TIS) for 30 minutes at room temperature and the
cleavage cocktail was evaporated using a stream of nitrogen. The pep-
tide was precipitated from solution with ice-cold diethyl ether (Et2O),
centrifuged at 4500 rpm for 5 minutes and the precipitate was dis-
solved in 50/50 MeCN/H2O, centrifuged at 4500 rpm for 5 minutes
and run using LC-MS and/or analytical HPLC.
Peptides containing cysteines were cleaved in a cleavage cocktail
(10 mL) of 94% TFA, 2.5% 1,2-ethanedithiol (EDT), 2.5% H2O and 1%
TIS. Peptides without cysteines were cleaved in a cleavage cocktail
(10 mL) of 95% TFA, 2.5% H2O and 2.5% TIS. The resin was stirred for
3 hours at room temperature and the cleavage cocktail was evaporated
using a stream of nitrogen. The peptides were precipitated from solution
with ice-cold Et2O, centrifuged at 4500 rpm for 5 minutes and the pre-
cipitate washed with ice cold Et2O. The peptide was dissolved in H2O/
MeCN + a few drops of glacial acetic acid and lyophilised overnight.
2.2.1 | Synthesis of the native μ-KIIIA peptides
1 and 2
The linear peptide was synthesized, cleaved from resin and purified as
described above. Peptide content was determined and the peptide was
oxidized at a concentration of 20 μM to avoid polymerization. The pep-
tide was oxidized using air oxidation in a 0.1 M ammonium carbonate
(NH4HCO3) buffer at pH 7.5, which was degassed using N2 for 1 hour
prior to use. The reaction was monitored using LC-MS, and typically
showed full conversion after 2-3 hours. The solution was then freeze
dried and the residual solid taken into MeOH, which was removed in
vacuo at 40 !C to remove most of the NH4HCO3-salt. The remaining
solid was then dissolved in a mixture of H2O/MeCN and purified as
specified above yielding both the major and the minor folded isomers.
2.2.2 | Synthesis of the hydrocarbon stapled
peptides 3, 4, 5 and 6 using ring closing-metathesis
The linear peptide was synthesized using solid phase peptide synthe-
sis (SPPS) as described above. The resin was suspended in dry dichlo-
roethane (DCE) (0.025 M) and 20 mol% Grubbs first catalyst was
added. The reaction was shaken for 2 hours at room temperature
excluding light. Following 3 × 1 minute dichloromethane (DCM)
washes the procedure was repeated. If full conversion had not been
attained the procedure was repeated in the microwave at 40 !C. After
the final RCM the resin was thoroughly washed (3 × 1 minute DMF,
3 × 1 minute isopropanol (iPrOH, 3 × 1 minute DCM) before resin
cleavage/global deprotection and purification as described above.
2.2.3 | Synthesis of the reduced hydrocarbon
stapled peptide 5
Resin containing hydrocarbon stapled peptide was swollen in N-methyl-
2-pyrrolidone (NMP) for 20 minutes, the solvent removed and a mixture
of triisopropylbenzenesulfonyl hydrazide (TPSH) (270 mg, 0.9 mmol,
9 eq.) and piperidine (180 uL, 1.8 mmol, 18 eq.) in 1 mL NMP was added.
The resin was kept at 48 !C for 2 hours. The procedure was repeated
4-5 times. The resin was then thoroughly washed (3 × 1 minute DMF,
3 × 1 minute iPrOH, 3 × 1 minute DCM) before resin cleavage/global
deprotection and purification as described above.
2.2.4 | Synthesis of the 1,4-triazole constrained
peptide 7
The linear peptide was synthesized using the azide- and alkyne α-methyl
amino acids S8 and S9 (see synthesis below) and cleaved from resin as
described above. The crude peptide was then dissolved in pure, degassed
H2O at 1 mg/mL concentration and 1 eq. sodium ascorbate (NaAsc),
1 eq. copper(II) sulfate pentahydrate (CuSO4.5H2O) and 8 eq. DIPEA
were added. The solution was stirred at room temperature overnight.
The reaction was then lyophilised and purified as described above.
2.2.5 | Synthesis of the 1,5-triazole constrained
peptide 8
The linear peptide was synthesized using the azide- and alkyne
α-methyl amino acids S8 and S9 (see synthesis below). The resin was
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dried for 24 hours in a desiccator before being taken into 2 mL dry
DMF and degassed for 20 minutes using argon gas. A 20 mol%
[Cp*RuCl(COD)] was added and the solution was degassed for a fur-
ther 10 minutes. The resin was then reacted in a microwave at 60 !C
for 6 hours. The resin was washed thoroughly (3 × 1 minute DMF,
3 × 1 minute iPrOH, 3 × 1 minute DCM) and cleaved/globally dep-
rotected and purified as described above.
2.2.6 | Synthesis of the lactam constrained
peptide 9
The linear peptide was synthesized using SPPS as described above,
except that for Asp3 the amino acid Fmoc-Asp(2-O-PhiPr)-OH was used
and for Lys7 the amino acid Fmoc-Lys(Mmt)-OH was used. The resin
was swollen in DCM and washed with a solution of 2% TFA in DCM
until the wash solution did not show a strong yellow color. The resin was
the washed thoroughly (3 × 1 minute DMF, 3 × 1 minute iPrOH,
3 × 1 minute DCM). The lactam was coupled using 1 eq. HCTU and
3 eq. DIPEA for 2 hours at room temperature and the coupling proce-
dure was repeated using fresh reagents. The resin was washed thor-
oughly (3 × 1 minute DMF, 3 × 1 minute iPrOH, 3 × 1 minute DCM) and
cleaved/globally deprotected and purified as described above.
2.3 | Circular dichroism
Circular dichroism was performed on a Jasco J-810 spectro-
polarimeter at 20 !C. Concentration was determined on a Nanodrop
and samples of 50 μM and 100 μM were made in pure H2O with a
maximum of 1% MeCN (final concentration) added for solubility.
Before running CD the concentrations were checked again. Each sam-
ple was run at two different concentrations (50 μM and 100 μM) with
0.2 nm increments, 10 nm/step and 2 seconds response time. Both
concentrations were compared to ensure that no dimerization/
oligomerisation had occurred. A control sample containing pure H2O
was subtracted and the graph smoothed.
The raw data was corrected to give mean residue ellipticity (MRE)





Where E is ellipticity in mdeg; l is pathlength in mm; c is peptide
concentration in μM; n is number of amide bonds in the peptide.
2.4 | Patch-clamp assay
Human embryonic kidney (HEK-293) cells expressing human Nav1.4
(SB Drug Discovery, Glasgow, UK) were cultured in minimum essential
media (MEM) medium with heat-inactivated Foetal Bovine Serum
(FBS) (10%) glutamine (2 mM) penicillin/streptomycin (50 units/mL),
blasticidin (2 μg/mL) and geneticin 418 (0.6 mg/mL). Cells were grown
in a humidified 5% CO2 incubator at 37 !C, grown to 70/80% conflu-
ence and passaged every 3 to 4 days using TrypLE express. For elec-
trophysiology experiments cells were dissociated with TrypLE then
resuspended in Ex-Cell ACF CHO medium and allowed to recover
with stirring for 45 minutes on the Q-patch.
Whole cell patch clamp experiments were performed on a
QPatch-16 automated electrophysiology platform (Sophion, Ballerup,
Denmark) using 16 channel QPlates. The extracellular solution (ECS)
contained 145 mM NaCl, 4 mM KCl, 1 mM MgCl2, 2 mM CaCl2,
10 mM HEPES and 10 mM glucose, pH 7.4. The intracellular solution
(ICS) contained 140 mM CsF, 1 mM EGTA, 10 mM HEPES, 5 mM
CsOH and 10 mM NaCl, pH 7.25. The holding potential was −90 mV
and channels were activated with a depolarizing step to 0 mV
for 10 ms.
Compounds were added to the cells in a cumulative fashion dur-
ing and for each cell, tetrodotoxin (TTX, 1 μM) was applied after the
compound applications of μ-conotoxin KIIIA or mimetics/controls to
act as a positive control as NaV1.4 and NaV1.6 are TTX sensitive.
A baseline correction was applied to the patch clamp data gener-
ated on the QPatch. This data was exported and analyzed using Gra-
phPad Prism 8.0 for Windows (San Diego, California). Nonlinear
regression was performed and a 4-parameter logistic fit was used with
the bottom of the curve constrained to 0. This fit was used to calcu-
late the IC50 and Hill Coefficient values. For minor isomer 2 at NaV1.6
the maximal block was not sufficient to generate IC50 or Hill Coeffi-
cient values.
2.5 | NMR assignment of stapled peptide alkene
isomers 3, 4 and 6
Samples were dissolved at between 0.2 and 1 mM in H2O with 5%
D2O and 250 p.p.m. TSP as a reference and 600 μL placed in a 5 mM
NMR tube (Wilmad 535-PP-7). All experiments were recorded using a
Bruker AVIII HD spectrometer operating at 599.87 MHz for 1H using
a TCI cryoprobe. For assignment and structure determination, 1H-1H
TOCSY, DQF-COSY, 1H-13C HSQC and 1H-1H NOESY spectra with
zero quantum suppression were recorded at 278 K. The NOESY data
for structure determination were collected at three different mixing
times (80, 200, 300 ms).[25] The spectra were assigned using CCPN
analysis 2.4 and the structures calculated with ARIA2.3/CNS1.2.[26,27]
From 100 structures calculated in the final iteration, the 20 lowest
energy were refined in explicit water and the structure with the low-
est overall energy used in further analysis.[28]
3 | RESULTS AND DISCUSSION
3.1 | Design and synthesis of peptidomimetics
Synthesis of native μ-KIIIA and stapled KIIIA-mimetics was achieved
with ChemMatrix Rink amide resin using standard Fmoc-based solid
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phase peptide synthesis (SPPS). The native linear μ-KIIIA peptide was
cleaved from the resin and purified before being oxidized to yield a
complex mixture (Scheme 1) from which the major isomer (1, eluting
first [see insert in scheme]) and the minor isomer (2, eluting second)
could be isolated. Disulfide connectivities of these two isomers have
previously been reported.[29] The two native isomers were tested to
ensure biological efficacy (vide infra).
As the published NMR structure of the native μ-KIIIA (isomer 1) is
α-helical[29] we replaced the disulfide bond network with synthetic
staples which have been shown previously to stabilize α-helical struc-
tures by bridging either one (i to i + 4) or two helical turns (i to i + 7)
(Figure 1).[30] A previous study on μ-KIIIA found six residues to be
important for biological activity: K7, W8, R10, D11, H12 and R14.[31]
We based the produced mimetics on this truncated 6-residue core
placing unnatural amino acids for stapling at the i and i + 4, or i and
i + 7, positions (Figure 1). We synthesized four different i, i + 4 staples,
three i, i + 7 staples and three controls (Figure 1).
We employed the hydrocarbon-stapling (HCS) strategy developed
by Verdine and co-workers[32] as the unnatural amino acids required
are commercially available.[33] The linear peptide 13 incorporating (R)-
N-Fmoc-α-(7-octenyl) alanine at position i and (S)-N-Fmoc-α-(4-pen-
tenyl)alanine at position i + 7 was prepared using standard Fmoc/tBu
SPPS methods. Linear peptide 14, incorporating two (S)-N-Fmoc-
α-(4-pentenyl)alanine residues in the i and i + 4 positions (Scheme 2C)
was also prepared to provide the shorter conformational constraint.
Ring-closing metathesis (RCM) was acheived using 20 mol% Grubbs
first catalyst at room temperature followed by resin cleavage, global
deprotection, and RP-HPLC purification. Applied to 13, this resulted
in both the trans (3) and cis (4) i,i + 7 stapled peptide isomers
(Scheme 2A) being isolated, whereas 14 yielded only the cis i,i + 4 sta-
pled peptide isomer (6) (Scheme 2C). We also produced the peptide
incorporating (R)-N-Fmoc-α-(7-octenyl)alanine at position i and (S)-N-
Fmoc-α-(4-pentenyl)alanine at position i + 7, but in this case no RCM
reaction was observed at room temperature, and heating produced a
complex mixture including epimers (detected by LC-MS analysis of a
cleaved sample). The configurational isomerism for 3, 4 and 6 was
confirmed by homonuclear decoupling 1H NMR experiments (Figures
S2 to S4 in SI).
Furthermore, as RCM of peptide 13 produced both the cis and
trans isomers 3 and 4 and to investigate further the effect of the
carbon-carbon double bond on the effectiveness of the hydrocarbon
constraint, we also produced the reduced i,i + 7 staple 5. After RCM
to produce peptides 3 and 4, the double bond was reduced on resin,
using triisopropylbenzenesulfonyl hydrazide under basic conditions
and elavated temperature to provide saturated stapled peptide
5 (Scheme 2B).[34]
We next wanted to explore the effectiveness of 1,4- and
1,5-triazole moieties as conformational constraints and surrogates for
the alkene isomers. To make the closest comparison with the
α-methyl substituted HCS mimetics, two α-methyl α-amino acids were
synthesized; alkyne S8 and azide S9 (Scheme S1) based on our previ-
ously published methodology.[35] These amino acids were used to syn-
thesize linear peptide 15, and the peptide then cleaved from the solid
support. Macrocyclisation of 15 was achieved using a Cu(I)-catalyzed
azide-alkyne cycloaddition (CuAAC) in solution (Scheme 2D) resulting
in the i,i + 4 stapled 1,4-disubstituted 1,2,3-triazole (7). We also
applied Ru(I)-catalyzed azide-alkyne cycloaddition (RuAAC) on resin
(Scheme 2E) to yield the 1,5-disubstituted 1,2,3-triazole i,i + 4 stapled
mimetic 8.
To compare our mimetics with the most potent μ-KIIIA mimetic
reported by Khoo et al.,[23] we synthesized the lactam analogue 9 using
a modified method, as the authors had used Boc-chemistry. To make
a direct comparison with the reported mimetic, we prepared this ana-
logue without α-methyl amino acid substitution. We employed an
orthogonal protection strategy, using 2-phenyl isopropyl ester (O-2-
PhiPr) protected Asp3, and 4-methoxytrityl (Mmt) protected Lys7,
that were simultaneously removed in 2% trifluoroacetic acid (TFA) in
dichloromethane. Macro-lactamisation was achieved on resin
(Scheme 2F) to provide the stapled peptide, which was cleaved and
purified by RP-HPLC.
Finally, we synthesized the three linear peptide controls 10, 11














SCHEME 1 Synthesis of native μ-KIIIA. The peptide was synthesized using standard SPPS protocols cleaved and purified before being
oxidized to yield several isomers of which two, 1 and 2, could be isolated. Insert: HPLC chromatogram showing the complex oxidation mixture
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i + 4 and i,i + 7 stapled peptides, respectively. Peptide 12 incorporates
Aib residues to investigate the effect of the α-methyl group in the i,
i + 7 peptidomimetics.
3.2 | Patch clamp evaluation of μ-KIIIA-mimetics
in hNaV1.4 and hNaV1.6 expressing HEK cells
The two native isomers (1-2), the stapled mimetics (3-9) and the con-
trols (10-12) were evaluated in a patch-clamp assay using human
embryonic kidney (HEK) cells expressing the human NaV1.4 (hNaV1.4)
or NaV1.6 (hNaV1.6) channels (Figure 2).
The major native isomer 1 gave an IC50 of 200 nM against hNaV1.4
and IC50 of 600 nM against hNaV1.6, whereas the minor isomer 2 was
#30 times (hNaV1.4) and markedly (hNaV1.6) less active than the major
isomer. Interestingly, the three i,i + 7 mimetics 3-5were the only mimetics
to show inhibition of the two channels; in hNaV1.4 the trans 3 and
reduced 5 staples showed almost equipotent inhibition, with the trans
staple 3 having a slightly better IC50 of 36.4 μM, compared to 38.9 μM
for the reduced staple 5 (Table 1). The cis stapled mimetic 4 was 3.9-fold
less active than the trans staple 3 with an IC50 of 140.9 μM. Against
hNaV1.6 channels, however, only the reduced staple 5 showed low micro-
molar inhibition with an IC50 of 76.23 μM, whereas the trans 3 and cis
4 staples were 1.4 - and 3.8-fold less potent, respectively. None of the i,
i + 4 mimetics 6-9 or the controls 10-12 showed any inhibition in either
channel type (Figure S1 in the SI), indicating that the longer i,i + 7 staples
seem to be required to provide a bioactive conformation.
3.3 | Circular dichroism of the μ-KIIIA-mimetics
The circular dichroism (CD) spectra of each of the peptides in water were
acquired to evaluate the degree of α-helicity induced by the different con-
formational constraints to that of the linear controls (Figure 3). All peptides
were run at two concentrations (50 and 100 μM) to ensure the results
were independent of concentration (data for 100 μM shown in Figure 3),
and then corrected to mean residue ellipticity (MRE; see SI).
The CD data for the three i,i + 7 HCS mimetics (3-5) and the two lin-
ear i,i + 7 controls (11 and 12) are presented in Figure 3A. CD data for the
four i,i + 4 stapled mimetics (6-9) and the linear i,i + 4 control (10) are
shown in Figure 3B. We examined the α-helicity of the compounds based
on the three extrema; the maxima at 190 nm and the two minima at
208 nm and 222 nm, which are known to be indicators of α-helical struc-
ture.[36] For the i,i + 7 staples there was a striking pattern; the trans-alkene
hydrocarbon mimetic 3 (dark green) showed most α-helical character,
followed by the reduced hydrocarbon-staple 5 (purple), with the cis-alkene
hydrocarbon mimetic 4 (dark blue) showing the least α-helical character.
Of the i,i + 4mimetics, the cis-alkene hydrocarbon mimetic 6 (red), showed
the most α-helical character, followed by the lactam-stapled mimetic
9 (light green). Interestingly, the 1,5-triazole stapled-mimetic 8 (light blue),
showed good α-helical character, whereas the CD curve from the
1,4-triazole stapled-mimetic 7 (orange) indicated a random coil conforma-
tion. We have previously shown that a 1,5-triazole bridge is a better disul-
fide surrogate than the 1,4-triazole analogue.[37,38] The current data
suggests that a 1,5-triazole bridge provides a similar type of constraint as a
cis-i,i + 4 hydrocarbon alkene staple and can effectively promote α-helical
F IGURE 1 The three i, i + 7 mimetics (3-5), the four i, i + 4 mimetics (6-9) and the three control mimetics (10-12) all based on the native
μ-KIIIA
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character in a peptide. The linear peptide controls 10, 11 and 12 all show
significantly less α-helical character than the stapled peptidomimetics.
The longer i,i + 7 staples seem to be required to provide a bioactive
conformation and biological activity against hNaV1.4 and hNaV1.6. How-
ever, there appears to be little correlation between the CD peptide helicity
of the i,i + 4 constrained analogues and bioactivity. Thus, we decided to
explore the secondary structure of the three most α-helical compounds (3,
5 and 6) according to CD using solution-phase NMR spectroscopy.
3.4 | Conformational evaluation of mimetics 3 and
5 by NMR
NMR spectroscopy has played a key role in providing the structures
of peptide toxins and facilitating structure activity relationship stud-
ies.[39] The use of NMR/X-ray structural methods provides an accu-
rate atomistic description of a peptide structure; however they
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only NMR spectroscopy can provide information concerning
solution structural dynamics. Therefore, for the most active all-
hydrocarbon mimetics 3 and 5 we produced modified CNS
topology/parameter descriptions (Figures S8 and S9), which in con-
junction with NOE-derived distance restraints, were used to com-
pute solution structures of these mimetics. Near complete
resonance assignment was achieved despite the degeneracy of the
alkane linker signals and the calculated structures were well
converged with good agreement with the experimental data
(Tables S1 and S2).
Peptidomimetics 3 and 5 are α-helical throughout the sequence
bounded by the linker residues and are structurally similar to each other
(0.52 Å backbone RMSD between the representative structures), con-
sistent with the similar bioactivity observed for each mimetic against
hNaV1.4 (Figure 4A). Comparison of each of the mimetics with the
structure of the native toxin (Figure 4B,C) shows that the amino acids
F IGURE 2 Patch-clamp testing of the native major 1 and minor 2 μ-KIIIA, and the active and partially active mimetics 3-5. (A) Testing of
compounds 1–5 in HEK293 cells expressing the human NaV1.4 channel (n = 9-24). (B) Testing of compounds 1–5 in HEK293 cells expressing the
human NaV1.6 channel (n = 7-27). (C-F) Patch clamp trace data from NaV1.4 (C, D) and NaV1.6 (E, F) cells, with the green and blue lines
representing the following (C) ≈ 50% block at 0.3 μm, maximum observed block at 10 μM (D) ≈ 50% block at 3 μM, maximum observed block at
100 μM (E) maximum observed block at 100 μM (F) ≈ 50% block at 1 μm, maximum observed block at 10 μM
TABLE 1 Comparison of the patch-clamp data for the two native m-KIIIA isomers, major (1) and minor (2), as well as the three most bioactive





Maximal block (%) and
mimetic concentration
at which this block occurred IC50 (μM)
Hill
coefficient
Maximal block (%) and
mimetic concentration
at which this block occurred
Major μ-KIIIA (1) 0.20 -0.66 84% (10 μM) 0.60 -1.17 92% (10 μM)
Minor μ-KIIIA (2) 6.02 -1.06 65% (10 μM) * * 22% (10 μM)
Trans-alkene (3) 36.4 -1.78 96% (100 μM) 108.0 -2.45 99% (300 μM)
Cis-alkene (4) 140.9 -3.53 96% (300 μM) 296.3 -2.57 45% (300 μM)
Reduced-staple (5) 38.9 -3.03 98% (100 μM) 76.23 -2.73 64% (100 μM)
Note: The compounds were tested in HEK293 cells expressing either the human NaV1.4 or the human NaV1.6 (n = 7-24). Data were fitted to a sigmoidal
dose response-curve and used to calculate IC50 and Hill Coefficient values. * denotes compounds where a curve fit was not possible.
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essential for bioactivity, namely K7, W8, R10, and D11,[31] are posi-
tioned similarly. The side chain of W8 in both mimetics is comparatively
unconstrained compared to the native toxin, and more so in mimetic 3,
which may explain the difference in activity at the two different NaV-
channels. In the native μ-KIIIA, W8 interacts with the Cys-rich core,
while in the mimetics the linkers are too distant to contact it.
F IGURE 3 Circular dichroism of the 10 mimetics and controls. (A) Circular dichroism data of the three i,i + 7 mimetics 3-5 and the two i,i + 7
controls 11 and 12. (B) Circular dichroism data of the four i,i + 4 mimetics 6-9 and the i,i + 4 control 10. Data are corrected for mean residue
ellipticity and recorded in water containing maximum 1% acetonitrile for solubility
F IGURE 4 Structures of μ-KIIIA mimetics
determined by NMR spectroscopy. (A) Both the
trans- (3) and reduced- (5) structures exhibit a
helical core and are structurally similar (0.52 Å
backbone RMSD). (B) The N-terminal residues of
both mimetics exhibit close structural similarity to
the native toxin (PDB:2LXG, gray) and project
similar functional groups along similar vectors.
(C) The C-terminal half of the mimetics continue in
a helical arrangement past the stapled linker
residue, whereas the native structure uncoils to
connect to the Cys-rich core producing significant
differences in structure around Arg14. Backbone
atoms are shown as sticks and sidechains as lines
with N and O colored blue and red, respectively. In
B & C, the views are related by a 180! rotation
around the page vertical and the helix axis of each
structure is shown as a thin cylinder and the
location of the Cys-rich core/stapled linker region
indicated as C/L
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A feature of the native structure is that, beyond H12, the helix
unwinds to make the turn into the Cys-rich core, whereas the
mimetics remain helical throughout, and thus do not effectively mimic
the C-terminal end of the native structure. The deviation is clearest in
the backbone conformation of R14, which in the mimetic structures is
firmly within a helical turn controlled by the adjacent
α,α-disubstituted nonnatural amino acid, whereas in the native struc-
ture the helix is essentially uncoiled (Figure 4C). Replacement of the
terminal Arg has previously been shown to greatly reduce the binding
of native μ-KIIIA to Nav1.4 and reduce the kon for binding to the
receptor.[31] It is possible that the inaccurate placement of this residue
in the mimetics could be responsible for their lower affinity.
We also attempted to determine the structure of i,i + 4 stapled
mimetic 6, which gave a similar CD spectrum, indicative of a high
α-helical content, to that of the i,i + 7 mimetic 3, but in contrast to
mimetic 3 did not show any bioactivity in the patch-clamp assays. The
NOE crosspeaks for the i,i + 7 mimetics, for example, 5, are well
resolved (Figure S12A) whereas the crosspeaks for mimetic 6 are
broadened (Figure S12B), indicating that the staple in mimetic 6 does
not stabilize the structure in a single conformation. As CD and NMR
are sensitive to structural changes on different timescales[40] this may
lead to seemingly contradictory results as observed for mimetic 6. In
the context of peptidomimetics, care must be taken not to over inter-
pret CD spectroscopic data. A helical curve does not necessarily mean
a rigid, highly constrained helical structure. NMR analysis of peptides
that are conformationally dynamic yet spend a significant proportion
of their time in a helical conformation can give rise to NOE cross
peaks that suggest only a helical structure. It is therefore important to
evaluate secondary structure using both methods. However, we
found that NMR provides more useful structural information that can
be used to rationalize biological data.
4 | CONCLUSIONS
The voltage gated sodium channels comprise a variety of related pro-
teins with distinct physiological and pharmacological properties with
specific subtypes localized to brain regions, skeletal muscle, peripheral
neurons, and heart. Local anesthetic drugs work by blocking these
channels and interrupting the flow of action potentials in neurons car-
rying nociceptive (and other sensory) information from the periphery
to the central nervous system. The μ-conotoxins present an opportu-
nity to create safe, selective anesthetics but in their native form these
peptides are unlikely to become lead drug compounds due to their
unfavorable physicochemical properties.
In this work, we produced simplified structures based on μ-KIIIA
by removing the complex disulfide-bonding network and replacing it
with chemical staple conformational constraints. We synthesized
seven stapled mimetics using a variety of chemistries and compared
them to the native μ-KIIIA isomers as well as three nonstapled control
compounds. Only compounds containing the i,i + 7 staples (3-5) gave
low micromolar inhibition of the two tested human sodium channels,
NaV1.4, from skeletal muscle and NaV1.6 from the CNS. Interestingly,
the reduced hydrocarbon-staple 5 could inhibit both hNaV1.4 and
hNaV1.6 channels equally well, whereas the trans-staple 3 showed
good inhibition of NaV1.4 but not NaV1.6, indicating this compound
could be used to selectively target one channel. The cis-staple 4 was
also active, but significantly less than the other two mimetics, having
a less favorable interaction with the binding sites. None of the other
mimetics or controls were active, indicating that the structure of these
compounds is key to biological activity. This was surprising, as Khoo
et al.[29] had previously shown lactam-staple 9 to be active in rodent
NaV1.4 and NaV1.6 channels. This species difference in receptor phar-
macology highlights the importance of testing compounds using
human VGSC assays in drug discovery programmes.
As the native μ-KIIIA adopts an α-helical conformation due to the
complex disulfide-bonding network, we explored the secondary struc-
ture of our mimetics using CD. The data indicate little correlation
between the CD peptide helicity and biological activity. Thus, we
decided to examine the two most active mimetics 3 and 5 as well as
the most helical i,i + 4 staple (the cis-staple 6), (according to CD), using
solution NMR spectroscopy.
The two active mimetics 3 and 5 have similar structures to the
native μ-KIIIA helix, but at the C-termini the stapled peptides' back-
bones continue the helical trajectory where the native structure
unwinds. As a result, the positioning of the backbone atoms of the
linker residue that substitutes S13 and of R14 deviate significantly
from those in the native structure, possibly explaining the lower activ-
ity of the mimetics. The NMR spectra of the cis-stapled mimetic 6 indi-
cate that the compound was not stabilized in a well-defined
conformation.
With an understanding of the structure-activity relationship of
these peptidomimetics, our future investigations will focus on devel-
oping potent, selective human NaV-channel blockers.
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